You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

411 Results
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
This hub contains tools and resources for primary care providers, colposcopists and other health care providers. This material supports the Ontario...
Document
New
Jun 2025
Document
New
Jun 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib / abiraterone,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
atezolizumab,
atezolizumab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025

Pages